[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350146-105":59,"doc-detail-350146-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-development-of-molecular-residual-disease-mrd-and-multi-cancer-early-detection-mced-using-liquid-biopsy-multiomics-with-artificial-intelligence-ai","Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)","","Early detection of cancer and accurate recurrence monitoring are major unmet needs in oncology. Conventional screening covers only a limited set of cancer types, leaving nearly half without established programs. Multi-cancer early detection (MCED) tests using circulating tumor biomarkers show promise, but early-stage sensitivity remains difficult, while MRD assays based on ctDNA are constrained by limited sensitivity and specificity. The study integrates multi-omics data to build sensitive MCED and MRD assays and assess clinical performance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-development-of-molecular-residual-disease-mrd-and-multi-cancer-early-detection-mced-using-liquid-biopsy-multiomics-with-artificial-intelligence-ai/350146/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-development-of-molecular-residual-disease-mrd-and-multi-cancer-early-detection-mced-using-liquid-biopsy-multiomics-with-artificial-intelligence-ai/350146.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the main problems this study targets in oncology?","Question",{"text":112,"@type":113},"The study addresses the need for earlier cancer detection and precise recurrence monitoring. It highlights limitations of conventional screening and current MCED/MRD assay sensitivity in early settings.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study plan to develop MCED and MRD assays?",{"text":117,"@type":113},"It integrates clinical information and biospecimens with comprehensive multi-omics profiling, including WGS, WES, WTS, proteomics, metabolomics, and microbiome data. Artificial intelligence is then used for multi-omics integration to build MCED and MRD assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What endpoints will be used to evaluate the assays?",{"text":121,"@type":113},"The primary endpoints are the sensitivity and specificity of the MCED and MRD assays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350146,1790143792,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","International Journal of Clinical Oncology (2026) 31:843–850  \n[https://doi.org/10.1007/s10147-026-03001-6](https://doi.org/10.1007/s10147-026-03001-6)  \nClinical development of molecular residual disease (MRD) and multi‑cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)  \nTaro Shibuki1,2 · Riu Yamashita3 · Tadayoshi Hashimoto2,4 · Takao Fujisawa2,5 · Mitsuho Imai2 · Junichiro Yuda6 · Takeshi Kuwata7 · Toshihiro Misumi8 · Yoshiaki Nakamura2,4 · Hideaki Bando2,4 · Kaname Kojima9 · Sayuri Tokioka9 · Ippei Chiba9 · Naoki Nakaya9 · Atsushi Hozawa9 · Seizo Koshiba9 · Nobuo Fuse9 · Sakae Saito9,10 · Ritsuko Shimizu9 · Woong‑Yang Park11,12 · Kengo Kinoshita9 · Takayuki Yoshino4  \nReceived: 21 November 2025 / Accepted: 21 February 2026 / Published online: 6 March 2026 © The Author(s) 2026  \nAbstract  \nBackground Early detection of cancer and precise recurrence monitoring remain major unmet needs in oncology. Conventional screening is limited to a few cancer types, leaving nearly half of cancers without established programs. Multi-cancer early detection (MCED) tests based on circulating tumor biomarkers have shown promise, but sensitivity for early-stage remains a challenge. In parallel, detection of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) has emerged as a powerful prognostic and predictive tool, though current assays remain limited in sensitivity and specificity. This study aims to integrate multi-omics data to develop more refined and highly sensitive MCED and MRD assays. Methods This study leverages clinical information and biospecimens from patients with cancer and cancer-naïve individuals. Samples from patients with cancers will be derived from the MONSTAR-SCREEN-3 study, while those from cancer-naïve individuals will be obtained from the Tohoku Medical Megabank Project. Comprehensive analyses will include wholegenome sequencing (WGS), whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), proteomics, metabolomics, and microbiome profiling using stool and saliva. Artificial intelligence (AI)-based multi-omics integration will be performed to develop novel MCED and MRD assays and to evaluate their clinical performance. The primary endpoints are the sensitivity and specificity of MCED and MRD assays.  \nDiscussion This is the first large-scale study to integrate comprehensive multi-omics profiling with AI for MCED and MRDassay development. The findings are expected to advance precision oncology by improving early diagnosis and recurrence monitoring.  \nTrial registration UMIN000053815, approved by the Institutional Review Board of the National Cancer Center Hospital East.  \nKeywords Multi-cancer early detection · Cancer screening · Cell-free DNA · Circulating tumor DNA · Multiomics · MCED  \nIntroduction  \nCancer is responsible for approximately 10 million deaths annually worldwide and remains the leading cause of death in Japan, with about one million new cases and 380,000 deaths each year. Patients diagnosed at an early stage have a favorable chance of long-term survival, while those diagnosed at an advanced stage experience markedly reduced survival rates [1, 2] . These findings underscore the critical  \nExtended author information available on the last page of the article  \nimportance of early diagnosis and prompt therapeutic intervention in improving patient outcomes. Even in developed countries such as the European Union (EU), the United States, and Japan, population-based cancer screening programs are currently established for only a limited number of cancer types, including breast, colorectal, gastric, lung, and cervical cancers. However, these screening methods are often neither simple nor easily accessible, and challenges such as procedural invasiveness and low participation rates are common across regions. Moreover, cancers other than these limited types still account for the majority of cancerrelated deaths, representing approximately 63.2","cbCaikEzPhlXO7rs","https://ap.wps.com/l/cbCaikEzPhlXO7rs","pdf",838252,"English","# Abstract\n## Background\n## Methods\n## Discussion\n# Introduction\n## Need for early detection and screening limitations\n## Blood-based approaches for MCED and MRD","[{\"question\":\"What are the main problems this study targets in oncology?\",\"answer\":\"The study addresses the need for earlier cancer detection and precise recurrence monitoring. It highlights limitations of conventional screening and current MCED/MRD assay sensitivity in early settings.\"},{\"question\":\"How does the study plan to develop MCED and MRD assays?\",\"answer\":\"It integrates clinical information and biospecimens with comprehensive multi-omics profiling, including WGS, WES, WTS, proteomics, metabolomics, and microbiome data. Artificial intelligence is then used for multi-omics integration to build MCED and MRD assays.\"},{\"question\":\"What endpoints will be used to evaluate the assays?\",\"answer\":\"The primary endpoints are the sensitivity and specificity of the MCED and MRD assays.\"}]","Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI) | PDF",1790087377,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71b7ed15155bd9368fee6b5800bb6725.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5a5a713bc15f970776aff6d07c0a70c.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10a47b109433a5c9d7f80caacf5e1fd6.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02b5a78c077d6c2253c68e632e3c6adb.webp",980,1301]